Sunday, July 12, 2026

Patent directory · USPTO A61K / A61P

Patents matching “inhibitor”

2,878 pharma patents match "inhibitor" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 2,878
Index total 30,257
Page 44 / 120

Quick answer

This filtered view shows 2,878 pharmaceutical patents matching "inhibitor" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

2,878 results for “inhibitor” · 30,257 patents in full index Clear search

  1. US 10485803

    Pyrimidine compounds as JAK kinase inhibitors

    Theravance Biopharma R&D IP, LLC · Granted Nov 26, 2019 · Expires Nov 21, 2039

    granted
  2. US 10479786

    Protein kinase inhibitors

    Princeton Drug Discovery, Inc · Granted Nov 19, 2019 · Expires Nov 14, 2039

    granted
  3. US 10478430

    Compounds useful as inhibitors of ATR kinase and combination therapies thereof

    Vertex Pharmaceuticals Incorporated · Granted Nov 19, 2019 · Expires Nov 14, 2039

    granted
  4. US 10479784

    Substituted pyrazin-2-amines as inhibitors of ATR kinase

    Vertex Pharmaceuticals Incorporated · Granted Nov 19, 2019 · Expires Nov 14, 2039

    granted
  5. US 10478435

    Use of CRAC channel inhibitors for the treatment of stroke and traumatic brain injury

    United States Government as represented by the Department of Veterans Affairs · Granted Nov 19, 2019 · Expires Nov 14, 2039

    granted
  6. US 10479798

    Six-membered ring benzo derivatives as DPP-4 inhibitor and use thereof

    East China University of Science and Technology · Granted Nov 19, 2019 · Expires Nov 14, 2039

    granted
  7. US 10471142

    Combination therapy using immunoglobulin and C1-Inhibitor

    THE GOVERNMENT OF THE UNITED STATES OF AMERICA · Granted Nov 12, 2019 · Expires Nov 7, 2039

    granted
  8. US 10471061

    Galactokinase inhibitors for the treatment and prevention of associated diseases and disorders

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Nov 12, 2019 · Expires Nov 7, 2039

    granted
  9. US 10471051

    Heterocyclic inhibitors of ERK1 and ERK2 and their use in the treatment of cancer

    Asana BioSciences, LLC · Granted Nov 12, 2019 · Expires Nov 7, 2039

    granted
  10. US 10471055

    Methods of treating cancer patients with farnesyltransferase inhibitors

    Kura Oncology, Inc. · Granted Nov 12, 2019 · Expires Nov 7, 2039

    granted
  11. US 10472387

    Inhibitors of glucocorticoid receptor

    ORIC PHARMACEUTICALS, INC. · Granted Nov 12, 2019 · Expires Nov 7, 2039

    granted
  12. US 2019337950

    BLOOD-BRAIN BARRIER-PENETRANT DOPAMINE-B-HYDROXYLASE INHIBITORS

    BIAL PORTELA & Cª S A [PT] · Granted Nov 7, 2019 · Expires Nov 2, 2039

    granted
  13. US 10463652

    Bach1 inhibitors in combination with Nrf2 activators and pharmaceutical compositions thereof

    VTV THERAPEUTICS LLC · Granted Nov 5, 2019 · Expires Oct 31, 2039

    granted
  14. US 10463663

    Pyridazinone compounds and their use as DAAO inhibitors

    Takeda Pharmaceutical Company Limited · Granted Nov 5, 2019 · Expires Oct 31, 2039

    granted
  15. US 10457725

    Methods of treating skin cancer by administering a PD-1 inhibitor

    REGENERON PHARMACEUTICALS, INC. · Granted Oct 29, 2019 · Expires Oct 24, 2039

    granted
  16. US 10451610

    Prediction of response to PARP inhibitors and combinational therapy targeting C-MET and PARP1

    The Board of Regents of the University of Texas System · Granted Oct 22, 2019 · Expires Oct 17, 2039

    granted
  17. US 10450285

    2-benzoylaminobenzamide derivatives as Bcl-3 inhibitors

    University College Cardiff Consultants Limited · Granted Oct 22, 2019 · Expires Oct 17, 2039

    granted
  18. US 10448637

    Inhibitors of GRB2-associated binding protein 1 (GAB1) and methods of treating cancer using the same

    Arizona Board of Regents on Behalf of the University of Arizona · Granted Oct 22, 2019 · Expires Oct 17, 2039

    granted
  19. US 10449182

    Sorafenib derivatives as p21 inhibitors

    The Regents of the University of California · Granted Oct 22, 2019 · Expires Oct 17, 2039

    granted
  20. US 10450572

    Androgen receptor variant inhibitors and methods of using

    Regents of the University of Minnesota · Granted Oct 22, 2019 · Expires Oct 17, 2039

    granted
  21. US 10441586

    CRMP2 SUMOylation inhibitors and uses thereof

    Arizona Board of Regents on Behalf of the University of Arizona · Granted Oct 15, 2019 · Expires Oct 10, 2039

    granted
  22. US 10442791

    DNA-PK inhibitors

    Vertex Pharmaceuticals Incorporated · Granted Oct 15, 2019 · Expires Oct 10, 2039

    granted
  23. US 10435399

    HDAC6 inhibitory heterocyclic compound

    Takeda Pharmaceutical Company Limited · Granted Oct 8, 2019 · Expires Oct 3, 2039

    granted
  24. US 10435355

    Inhibitors of fatty acid amide hydrolase (FAAH) enzyme with improved oral bioavailability and their use as medicaments

    The Regents of the University of California · Granted Oct 8, 2019 · Expires Oct 3, 2039

    granted